Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.79 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140751 | 0.90 | HPGD (1.00) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL13486221 | 0.90 | HPGD (1.00) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL244547 | 0.90 | HPGD (1.00) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL5970063 | 0.89 | HPGD (1.00) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL14085095 | 0.84 | HPGD (0.73) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL13779946 | 0.84 | HPGD (0.97) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL8475795 | 0.83 | HPGD (0.71) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL13216391 | 0.83 | HPGD (0.71) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL5524809 | 0.83 | HPGD (0.71) | HPGDTSHRRECQLCYP1A2CYP3A4 | |
| SCHEMBL108225 | 0.81 | ALDH1A1 (0.90) | HPGDTSHRRECQLCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2025-07-03 | — | — | US | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| CN-119504698-A | Method for preparing CX546 by using sulfur hexafluoride | 国网安徽省电力有限公司电力科学研究院 | 2025-02-25 | — | — | CN | claimed |
| US-20250032431-A1 | METHODS OF TREATING RETT SYNDROME USING FENFLURAMINE | ZOGENIX INTERNATIONAL LIMITED (GB) | 2025-01-30 | — | — | US | claimed |
| US-12144787-B2 | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) | ZOGENIX INTERNATIONAL LIMITED (GB) | 2024-11-19 | — | — | US | claimed |
| US-20230285322-A1 | Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-09-14 | — | — | US | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | claimed |
| CN-113932789-B | Data transmission method and system for optical fiber gyroscope | 宁波圣荣电子科技有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-216012261-U | Optical fiber gyroscope | 舟山市向海电子科技有限公司 | 2022-03-11 | — | — | CN | claimed |
| EP-2948135-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-01-02 | — | — | EP | claimed |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-11 | — | — | US | claimed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | claimed |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2015-12-17 | — | — | US | claimed |
| EP-2948135-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2015-12-02 | — | — | EP | claimed |
| WO-2014117089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-31 | — | — | WO | claimed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | claimed |
| WO-2008027648-A2 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | HPGD 1202/4885TSHR 3499/4885RECQL 4057/4885 |
| US-20250032431-A1 | METHODS OF TREATING RETT SYNDROME USING FENFLURAMINE | HTR2C, HTR2A, HTR1A | HPGD 3905/4885TSHR 430/4885RECQL 656/4885 |
| US-12144787-B2 | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) | CDKL5, HTR5A, CDKL1 | HPGD 4022/4885TSHR 1269/4885RECQL 848/4885 |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | HPGD 1983/4885TSHR 2725/4885RECQL 4750/4885 |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | HPGD 3434/4885TSHR 3042/4885RECQL 3635/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | HPGD 3070/4885TSHR 958/4885RECQL 2820/4885 |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | MECP2, GRIN2A, GRIN2C | HPGD 2404/4885TSHR 4233/4885RECQL 3817/4885 |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2A, GRIN2C, GRIN2D | HPGD 1564/4885TSHR 3490/4885RECQL 4525/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | HPGD 2739/4885TSHR 2530/4885RECQL 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.